Area of research
Oncology · Genetics
Research interest
Research interests include Glioma Diagnosis and Treatment, Immunotherapy and Immune Responses, CAR-T cell therapy research, and Cancer Immunotherapy and Biomarkers.
IMMU-79. An Updated Analysis of PD1 and Immune Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N13
Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade
KR158 spheres harboring slow-cycling cells recapitulate GBM features in an immunocompetent system
Effects of immune checkpoint blockade on antigen‐specific CD8<sup>+</sup> T cells for use in adoptive cellular therapy
Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging
Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy
ATIM-15. SUSTAINED COMPLETE RADIOGRAPHIC RESPONSE AND PROLONGED SYSTEMIC IMMUNE ACTIVATION IN A PATIENT WITH MGMT UNMETHYLATED MIDLINE GLIOBLASTOMA RECEIVING CMV pp65-LAMP RNA-PULSED DENDRITIC CELL VACCINES
ATIM-34. SINGLE-CELL RNA SEQUENCING REVEALS DYNAMIC IMMUNE RESPONSE CHANGES IN GLIOBLASTOMA PATIENT WITH DURABLE COMPLETE RESPONSE TO CMV PP65-LAMP RNA-PULSED DENDRITIC VACCINES
TMIC-29. METABOLIC INTERACTIONS BETWEEN TREATMENT-RESISTANT SLOW-CYCLING CELLS AND THE IMMUNE SYSTEM IN HIGH-GRADE GLIOMA
IMMU-13. MECHANISMS OF IMMUNOLOGICAL ESCAPE DURING ADOPTIVE CELLULAR THERAPY IN HIGH GRADE GLIOMA
IMMU-24. A COMPREHENSIVE IN SILICO APPROACH TO DISCOVERING TUMOR REJECTION ANTIGENS IN MALIGNANT BRAIN TUMORS
IMMU-27. IMMUNE CHECKPOINT BLOCKADE OF EX VIVO EXPANDED T CELLS FOR USE IN ADOPTIVE CELLULAR THERAPY (ACT) FOR GLIOBLASTOMA
EXTH-15. INCREASING THE TRAFFICKING OF DENDRITIC CELLS VIA CXC CHEMOKINE SIGNALING PATHWAY LEADS TO IMPROVED ANTI-TUMOR EFFICACY OF DENDRITIC CELL VACCINES
The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
IMMU-45. DOSE MODULATION OF TEMOZOLOMIDE HAVE DISTINCT EFFECTS ON HOST RESPONSE TO PD-1 BLOCKADE
IMMU-56. CXCR1/2 MODIFIED CARs CO-OPT RADIATION-INDUCED IL-8 FOR ENHANCED CHEMOTAXIS OF THE CAR T CELLS AND MAXIMAL ANTI-TUMOR EFFICACY
IMMU-43. RNA-MODIFIED T CELLS AS A NON-INVASIVE AND EFFICACIOUS STRATEGY TO DELIVER THERAPEUTIC MACROMOLECULES LOCALLY TO INTRACRANIAL TUMORS
STEM-09. CANCER STEM CELL IMMUNOEDITING
CD70, a novel target of CAR T-cell therapy for gliomas
Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM
CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression
CD70 as a novel target of CAR-T-cell therapy for gliomas.
CD70 as a critical mediator of tumor progression and immunosuppression in gliomas.
TMIC-26. IMMUNOMODULATION WITH TEMOZOLOMIDE TO IMPROVE EFFICACY OF IMMUNE CHECKPOINT INHIBITION FOR THE TREATMENT OF GLIOBLASTOMA
STEM-09. TREATMENT-RESISTANT SLOW-CYCLING CELLS SUPPORT METABOLIC HETEROGENEITY AND ADAPTABILITY IN GLIOBLASTOMA
IMMU-25. ENHANCED T CELLS TUMOR RECOGNITION USING DENDRITIC CELLS PULSED WITH CHIMERIC RNAs ENCODING FULL-LENGTH LAMP-1 FUSION CONSTRUCTS
TMIC-12. TMZ RESULTS IN PRIMING OF HOST IMMUNITY AND CHANGES IN GBM TUMOR PDL-1 EXPRESSION IN A DOSE DEPENDENT FASHION THAT CAN BE LEVERAGED FOR COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE
IMST-33. ENHANCED T CELL ACTIVATION USING DENDRITIC CELLS PULSED WITH CHIMERIC RNAs ENCODING FULL-LENGTH LAMP-1 FUSION CONSTRUCTS
IMST-24. COMBINATION OF VEGF-A AND PD-1 BLOCKADE MAY ENHANCE ANTITUMOR EFFICACY IN GBM